JTT-861 / Japan Tobacco - LARVOL DELTA

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=314 | Completed | Sponsor: Akros Pharma Inc. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ May 2026

Trial completion • Trial completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=314 | Active, not recruiting | Sponsor: Akros Pharma Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2026 ➔ May 2026

Enrollment closed • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial primary completion date: Feb 2027 ➔ Aug 2026

Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial completion date: Sep 2025 ➔ Feb 2027 | Trial primary completion date: Sep 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects with Heart Failure with Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Trial completion date: Jun 2025 ➔ Sep 2025 | Initiation date: Aug 2023 ➔ Dec 2023

Trial completion date • Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc.

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Akros Pharma Inc. | Phase classification: P2a ➔ P2

Phase classification • Cardiovascular • Congestive Heart Failure • Heart Failure

POWER-HF: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (clinicaltrials.gov) - P2a | N=300 | Recruiting | Sponsor: Akros Pharma Inc.

New P2a trial • Cardiovascular • Congestive Heart Failure • Heart Failure